Heart failure & cardiomyopathies
Renal Ultrasonography Predicts Worsening Renal Function in Patients with Heart Failure Under Tolvaptan Administration
Authors' conclusion
Tolvaptan increased the PSV and EDV of the interlobar artery, which may mean tolvaptan increased renal blood flow. The renal artery AT may be a surrogate for worsening renal function.
Study context
- Population
- Patients with decompensated HF, January 2014–March 2019
- Participants
- 201 patients
- Comparison
- Early vs late tolvaptan administration; renal ultrasonography before vs after tolvaptan
- Earlyn = 104
- Laten = 97reference
Methodological detailsprospectively randomized
- Prospectively randomized
Primary result
As reported in the abstract
Change in interlobar artery velocities, before vs after tolvaptan
- After tolvaptan vs Before tolvaptan: P = 0.002
- After tolvaptan vs Before tolvaptan: P = 0.002
- After tolvaptan vs Before tolvaptan: P = 0.001
- After tolvaptan vs Before tolvaptan: P = 0.003
Further findings
Renal artery acceleration time (AT) and estimated glomerular filtration rate (eGFR)
- Δmax AT negatively correlated with eGFR, beta = −0.2354
- P = 0.044
- Δmean AT negatively correlated with eGFR, beta = −0.2477
- P = 0.035
Urine output, oral water intake, water intake–urine volume difference
- Significantly increased during tolvaptan administration
Body weight, BP, heart rate, eGFR; renal artery peak-systolic velocity (PSV), AT and resistance index
- Changes comparable in both groups
Original publication
Renal Ultrasonography Predicts Worsening Renal Function in Patients with Heart Failure Under Tolvaptan Administration. ESC Heart Fail. Published 12 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →